Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the successful ...

As recently as last month, the biotech had been setting out plans for a phase 3 trial of the combo treatment for later in ...

The firm will pause development of lunresertib and camonsertib while focusing on development of two newer programs.

Merck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in a phase 1 study. Short for ataxia telangiectasia and Rad3-related ...

Exposure to radiation kills cells from the same tumors in different ways, and some are far more useful for saving lives than ...

Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel DNA-damage ...

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions ...

It is our mission to be the go to leaders in the aviation industry. GlobalAir.com is your partner in connecting you with relevant information and resources.

After hours: January 3 at 7:55:42 p.m. EST ...